Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABX464 plus methotrexate in moderate to severe active rheumatoid arthritis
2018-004677-27Phase 2Completed
- Sponsor
- Abivax
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of obefazimod in rheumatoid arthritis (RA) (3 arms), sponsored by Abivax. Primary endpoint: Incidence of treatment-emergent adverse events. Started Mar 2019; status: completed.
02
Drugs
obefazimod
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2018-004677-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004677-27.